Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced ...
J.P. Morgan turned cautious on the eVTOL sector as it attempted to balance the near-term relativeshare price outperformance ...
J.P. Morgan releases its quarterly look-ahead days before the entire biopharma industry descends on San Francisco for the ...
Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase 3 trials across multiple melanoma ...
More than 8,000 healthcare professionals will descend on San Francisco starting Monday for the 43rd annual J.P. Morgan ...
The fires, which are still not under control and have killed at least five people, are likely to cost more than $50 billion in overall losses, the analysts said. Late Thursday, Accuweather pinned the ...
The $13.7 billion iShares U.S. Equity Factor Rotation Active ETF from BlackRock added $11.7 billion in assets in 2024 after ...
The fires sweeping across Los Angeles are now on track to cause about $20 billion of insured losses, according to an estimate ...
The Los Angeles wildfires are now expected to exceed $20B, J.P. Morgan analyst Jimmy Bhullar estimated Thursday, doubling his ...
A preliminary report by Accuweather estimated the cost of the wildfires ravaging L.A. County at more than $50 billion, a ...
JPMorgan Income ETF’s JPIE experienced, specialized, and collaborative team earned it a People Pillar rating boost to High, ...
STAT reporters discuss why a looming patent cliff could lead to more pharmaceutical deal-making and a new obesity startup.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback